+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness of adding the drug tirzepatide to ongoing ixekizumab therapy in adults with moderate-to-severe plaque psoriasis who are also overweight or obese with at least one weight-related health condition. This Phase 4 study aims to assess how well this combination works in real-world clinical practice over a period of up to 12 months. Participants will continue their prescribed ixekizumab treatment and start taking tirzepatide through subcutaneous injections according to approved guidelines. The study is designed as a single-arm, open-label trial where all participants receive tirzepatide along with ixekizumab. The treatment period covers about one year, during which the response to this combined therapy will be closely observed. Throughout the study, participants will undergo regular assessments to measure improvements in their skin condition and weight. Key outcomes include the percentage achieving minimal impact on quality of life related to dermatology and at least 10% weight loss after 12 months. Additional evaluations at 6 and 12 months will monitor skin involvement, global physician and patient assessments, and weight changes. Safety and tolerability will also be followed during this time.

Age: 18Years +All GendersPhase 4
38 locations
P

Actively Recruiting

Researchers are evaluating Narrowband Ultraviolet-B UVB phototherapy as a treatment for adults with moderate to severe chronic plaque-type psoriasis. This pilot study involves 30 patients and aims to assess the response to this phototherapy given three times a week over 12 weeks, followed by evaluations to see how well the treatment effects last through week 36. The study is conducted at a single center and sponsored by the Psoriasis Treatment Center of Central New Jersey. Participants will receive increasing doses of Narrowband UVB phototherapy three times weekly for 12 weeks. This open-label treatment phase is followed by periodic assessments every six weeks up to week 36 to monitor the maintenance of treatment response. The phototherapy is delivered using a device designed to emit ultraviolet B light, targeting the skin affected by psoriasis. During the study, patients will attend regular phototherapy sessions and follow-up visits. Researchers will evaluate changes in psoriasis severity using the Psoriasis Area Severity Index PASI score at 12 weeks as the primary outcome. Additional assessments include the Physicians Global Assessment, Body Surface Area affected, and a combined measure of these two at 12 weeks. Patients must be in good general health apart from psoriasis and able to comply with the treatment schedule and visits throughout the trial.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the effects of DUOBRII in combination with biologic therapy in adults with psoriasis affecting 2% to 10% of their body surface area. This open-label pilot study involves 25 participants who have been receiving biologic treatments for at least 24 weeks. The study aims to assess how DUOBRII impacts psoriasis when added to ongoing biologic therapy. Participants will apply DUOBRII daily for the first 4 weeks, followed by every other day for the next 4 weeks, over a total treatment period of 12 weeks. This study does not include a placebo group and is conducted at a single center. The focus is on observing changes in the extent of psoriasis during and after the treatment period. During the study, participants will be monitored for improvements in their psoriasis, specifically measuring the percentage of body surface area affected at 8 weeks. Researchers will collect data on skin condition and treatment adherence. The study includes assessments at baseline and follow-up visits throughout the treatment period to evaluate safety and efficacy.

Age: 18Years +All GendersPhase 4
1 location
S

Actively Recruiting

This research aims to evaluate the combination of dupilumab and narrowband UVB phototherapy for adults with moderate to severe atopic dermatitis. The study is a 24-week open-label trial sponsored by the Psoriasis Treatment Center of Central New Jersey, focusing on the safety and effectiveness of these treatments in improving skin condition. Participants will receive dupilumab 300mg along with narrowband UVB phototherapy three times a week for the first 12 weeks. Following this, they will continue with dupilumab alone for an additional 12 weeks. This treatment plan allows researchers to observe the effects of combined therapy followed by monotherapy. During the study, participants will be monitored for changes in their skin using the Investigators Global Assessment Score at 12 weeks. Researchers will assess skin improvements and monitor safety throughout the 24 weeks. Participants can expect regular visits for treatment and evaluations to track progress and any side effects.

Age: 18Years +All GendersPhase 4
1 location
S

Actively Recruiting

This research aims to evaluate the use of Enstilar foam in adults with plaque psoriasis who have a body surface area affected between 2% and 10% and a physician global assessment score of 2 or higher. Participants are already receiving treatment with etanercept or adalimumab for at least 24 weeks. The study is an open-label phase 4 trial investigating the addition of Enstilar to these ongoing treatments. Participants will apply Enstilar topical foam once daily for the first 4 weeks, followed by every other day for the next 12 weeks, while continuing their etanercept or adalimumab treatments. This regimen is designed to assess how Enstilar works alongside these medications in managing psoriasis symptoms. Throughout the 16-week study, researchers will monitor participants skin condition using the Physician Global Assessment combined with body surface area improvement as the primary outcome. Secondary outcomes include body surface area improvement alone, quality of life changes measured by the Dermatology Life Quality Index, and itch severity using a numerical rating scale. Participants will have regular evaluations to track these measures and assess safety.

Age: 18Years +All GendersPhase 4
1 location
S

Actively Recruiting

This research aims to evaluate the use of Ilumya, with or without Halog ointment, in adults with moderate to severe plaque psoriasis. The study focuses on patients who have this chronic skin condition characterized by widespread plaques and aims to assess the effectiveness and safety of combining these treatments. Participants will receive Ilumya injections of 100mg under the skin at the start of the study, week 4, and week 16. At week 16, if patients still have 3% or more of their body surface area affected by psoriasis, they will add Halog ointment 0.1%, applied twice daily for four weeks. Those with less than 3% affected will continue only with Ilumya. Follow-up visits will occur at weeks 20 and 24 to monitor progress. Throughout the study, participants will be regularly evaluated for changes in their affected skin area and overall condition. Researchers will measure body surface area affected by psoriasis at 16 weeks as the main outcome. Safety and effectiveness will be monitored until week 24. The total involvement spans from the initial treatment through the follow-up visits over 24 weeks.

Age: 18Years +All GendersPhase 4
1 location
S

Actively Recruiting

This research aims to evaluate the effect of adding Enstilar Foam to patients with plaque psoriasis who have been treated with Taltz for at least 24 weeks. The study focuses on adults with a body surface area BSA affected by psoriasis between 3% and 8%. The trial is conducted at a single center and involves 25 participants to assess the combination treatment. Participants receive topical Enstilar foam while continuing their Taltz treatment. This is an open-label study, meaning both researchers and participants know the treatment being administered. The study focuses on how this combination affects psoriasis over a period of 4 weeks, with no placebo or masking involved. During the study, participants will undergo evaluations to measure the extent of their psoriasis, particularly looking at the body surface area affected. The main outcome measure is achieving a BSA score of 0 or 1 at 4 weeks. Participants will be monitored for safety and treatment adherence throughout the study duration. The total participation lasts for the time of treatment and follow-up within the 4-week period.

Age: 18Years +All GendersPhase 4
1 location